Industry expert will lead company’s expansion to more flexible and fit-for-purpose scientific solutions to address growing oncology evidence needs
Flatiron Health is pleased to announce the appointment of Matthew Reynolds, PhD, as Vice President, Scientific Engagement. In his new role, Dr. Reynolds will work closely with biopharma customers to understand their unique oncology evidence needs, scope and define scientific solutions tailored to address these goals, and advance Flatiron's capabilities in real-world evidence (RWE) analytic services.
“Flatiron is redefining how to service clients with analytic, scientific, analytics and consultative expertise. This requires revolutionary thought leaders who have a deep and comprehensive understanding of integrated real-world evidence solutions,” said Carolyn Starrett, Flatiron CEO. “I’m thrilled to welcome Matt Reynolds to our team. As an industry leader in RWE, his extensive experience and expertise will continue to advance our scientific efforts, further enabling us to solve problems for our customers by pairing the highest quality real-world data with the top real-world evidence experts.”
Prior to Flatiron, Dr. Reynolds was the Vice President of Scientific Affairs at IQVIA. During his time at IQVIA, he worked with the scientific and business development teams within the U.S. Real-World Division to shape innovative solutions for a broad spectrum of real-world pharmaceutical needs, spanning regulatory, drug safety, medical affairs, health economics, clinical development, and commercial use cases.
“I'm excited to join Flatiron Health, a global leader and pioneer in real-world data, and help lead the expansion of our evidence business to deliver a full spectrum of services including study design, analytics, and scientific dissemination,” said Dr. Reynolds. “Flatiron is driving innovations across the cancer care ecosystem and I am inspired to be a part of an organization that is committed to improving and extending lives by learning from the experience of every person with cancer.”
Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, we continue to transform patients’ real-life experiences into knowledge and create a more modern, connected oncology ecosystem. Flatiron Health is an independent affiliate of the Roche Group. Flatiron.com @FlatironHealth
Media Contact: Nina Toor